NO钱包

Be the most trusted biotech company

2026-01-30

Henlius and Chongqing Pharmaceutical Group Enter into Strategic Collaboration for Shared Growth
2026-01-27

Henlius Receives an IND Approval for Its PD-L1-Targeting ADC HLX43 in Combination with Anti-PD-1 mAb Serplulimab and Novel Anti-EGFR mAb HLX07
2026-01-20

Henlius Receives NMPA Approval to Initiate Phase 1b/2 Clinical Trial of Novel SIRPα-Fc Fusion Protein HLX701 for Advanced RAS/BRAF Wild-type Colorectal Cancer
2026-01-16

Henlius Showcases “Globalisation 2.0” Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
2026-01-14

Henlius Strengthens Autoimmune-Inflammation Portfolio by In-Licensing a Novel, Best-in-Class Potential Anti-IL-1RAP mAb
2026-01-13

Henlius' Fifth U.S. Filing Product Bevacizumab Biosimilar HLX04 Receives FDA BLA Acceptance
2026-01-11

Results from Neoadjuvant studies of Henlius' serplulimab in colon/rectal cancer released at ASCO GI 2026
2026-01-09

ASCO GI 2026 | Henlius Accelerates Global Phase 3 Head-to-Head Development of HLX22 as First-Line Treatment for HER2-Positive Gastric Cancer
2026-01-09

Henlius Debuts Phase 2 Results for Its Broad Anti-tumor PD-L1 ADC HLX43 in Second-Line or Subsequent Treatment of Esophageal Squamous Cell Carcinoma at ASCO GI 2026